CORT Stock — Corcept Therapeutics Incorporated: Cash, EV, Pipeline

Share price

$110.29

Market cap

$11,922.2M

Cash

$308.2M

Enterprise value

$11,614.0M

Balance sheet

Cash	$308.2M
Debt	$0.0M
Net cash	$308.2M
Enterprise value	$11,614.0M
Basic shares	118.4M shares
Fully diluted shares	140.7M shares
Fully diluted market cap	$15,522.0M
Cash per share	$2.60

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CORT daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Oct 24, 2026	Relacorilant 150 mg once daily (QD)	Phase 2	Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms	—
Now - Oct 24, 2026	Miricorilant	Phase 1	Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-Associated Steatohepatitis (MASH); Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	—
Oct 13 - Nov 24	Miricorilant (Cohort A)	Phase 2	Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-associated Steatohepatitis (MASH)	—
Oct 13 - Nov 24	Nenocorilant 200 mg	Phase 2	Neoplasms	—
Nov 12 - Dec 24	Dazucorilant 300 mg	Phase 2	Amyotrophic Lateral Sclerosis	—
Dec 11, 2026 - Jan 22, 2027	Miricorilant	Phase 1	Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic; Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)	—
Jan 12 - Feb 23	relacorilant	Phase 2	Cushing Syndrome	—
Oct 13 - Nov 24	Relacorilant	Phase 2	Adenocarcinoma; Carcinoma, Pancreatic Ductal	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Korlym

Approved · Active Modality: small molecule

Aliases mifepristone

Target glucocorticoid receptor (GR)

Indications

Hypercortisolism (Cushing's syndrome) (Approved)

Status note Marketed in the U.S. since 2012 for hypercortisolism; authorized generic version launched June 2024.

Relacorilant

Approved · Active Modality: small molecule

Aliases Lifyorli

Target glucocorticoid receptor (GR)

Partnerships University of Chicago: randomized placebo-controlled Phase 2 of relacorilant + enzalutamide in prostate cancer (pre-prostatectomy), licensed patents. ARCAGY-GINECO: Phase 2 STELLA trial of relacorilant + nab-paclitaxel in 50 cervical cancer patients

Indications

Hypercortisolism (Phase 3)
Platinum-resistant ovarian cancer (with nab-paclitaxel) (Approved)
Pancreatic cancer (with nab-paclitaxel + gemcitabine) (Phase 2)
Cervical cancer (with nab-paclitaxel) (Phase 2)
Prostate cancer (with enzalutamide) (Phase 2)
Other solid tumors (Phase 2)

Catalysts

— fourth quarter of 2026

Status note Hypercortisolism: NDA submitted December 2024; FDA issued Complete Response Letter December 30, 2025. Approved as Lifyorli in March 2026 in combination with nab-paclitaxel for platinum-resistant ovarian cancer. Phase 2 trials: BELLA (ovarian, Part A enrollment completed December 2025), TRIDENT (pancreatic, initiated December 2025), STELLA (cervical, initiating Q1 2026).

Nenocorilant

Stage not disclosed · Active Modality: small molecule

Target glucocorticoid receptor (GR)

Indications

Cancer (with immunotherapy) (Stage not disclosed)

Status note Proprietary selective cortisol modulator; trial stage not stated in excerpts.

Miricorilant

Phase 2 · Active Modality: small molecule

Target glucocorticoid receptor (GR)

Indications

MASH (Phase 2)

Status note Selective cortisol modulator for MASH. Phase 1b completed; randomized double-blind placebo-controlled Phase 2 initiated October 2023.

Dazucorilant

Phase 2 · Active Modality: small molecule

Target glucocorticoid receptor (GR)

Indications

ALS (Phase 2)

Status note Selective cortisol modulator for ALS; FDA Fast Track Designation and orphan drug status. Phase 2 DAZALS (249 patients, 24 weeks) did not meet its primary endpoint. No discontinuation language in the excerpts.

Per-asset detail extracted from the 10-Q filed 2026-07-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Nab-paclitaxel 80 mg/m^2
Lead indication	Ovarian Neoplasm
Lead phase	Phase 3
Active trials	9
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05257408	Phase 3	Active, not recruiting	Sponsor	CORT	—	Ovarian Neoplasm; Fallopian Tube Neoplasms; Peritoneal Neoplasms	—
NCT05407324	Phase 2	Recruiting	Sponsor	CORT	—	Amyotrophic Lateral Sclerosis	—
NCT03604198	Phase 2	Active, not recruiting	Sponsor	CORT	—	Cushing Syndrome	—
NCT07259317	Phase 2	Recruiting	Sponsor	CORT	—	Adenocarcinoma; Carcinoma, Pancreatic Ductal	—
NCT06906341	Phase 2	Recruiting	Sponsor	CORT	—	Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms	—
NCT06108219	Phase 2	Active, not recruiting	Sponsor	CORT	—	Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-associated Steatohepatitis (MASH)	—
NCT07276373	Phase 2	Recruiting	Sponsor	CORT	—	Neoplasms	—
NCT07553663	Phase 1	Recruiting	Sponsor	CORT	—	Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic; Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)	—
NCT06947304	Phase 1	Active, not recruiting	Sponsor	CORT	—	Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-Associated Steatohepatitis (MASH); Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	—
NCT06099769	Phase 2	Recruiting	Collaborator	Memorial Sloan Kettering Cancer Center	—	Metastatic Breast Cancer	—
NCT06689254	Phase 2	Recruiting	Collaborator	Christiaan Vinkers	—	Treatment-resistant PTSD	—

Sponsor-matched active trials from ClinicalTrials.gov (9 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 11 active trials for Corcept Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	0	-8,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CORT — Corcept Therapeutics Incorporated

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders